A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.
Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I, Katz S, Krone CL, Vander Vliet M, Stevens C, Sherman ML, Jacobson E, Bleday R.
Inflamm Bowel Dis. 2006 Jul;12(7):558-65.PMID: 16804392 [PubMed - indexed for MEDLINE]Related articlesFree article